New study; LUCAS CPR saves lives at cardiac arrest in the catheterization laboratory
December 18, 2009, Lund, Sweden
A group of patients that previously has been close to impossible to save, can now be saved with help of LUCAS mechanical chest compressions and continued coronary intervention.
The catheterization laboratory of Lund University Hospital in Lund, Sweden, has since 2004 used the LUCAS Chest Compression System to sustain blood circulation in patients who have gone into a cardiac arrest during interventional treatment of myocardial infarction. The results which are published this week in the Journal of Resuscitation are very encouraging. During five years 11 patients out of 38 patients have been saved with a good outcome with the help of effective and consistent LUCAS chest compressions during a continued intervention. Dr. Henrik Wagner, one of the study authors, concludes that few, if any of these patients, would have survived without the use of LUCAS.
“Rescuers who provide manual chest compressions interfere both with the X-ray equipment and the image. The attempts to reopen the coronary artery must be interrupted frequently while manual chest compressions are provided. The situation becomes very chaotic and stressful. It becomes a compromise between patient circulation and continued coronary intervention. In addition to this are rescuers, who provide manual CPR, exposed to high doses of X-ray”, says Dr. Henrik Wagner. “LUCAS interferes less and is mainly radiotranslucent. It allows us to visualize the coronary arteries in the most common X-ray projections. While LUCAS sustains circulation, the situation calms down considerably in the lab and we can focus on treating the cause of the arrest, which is often a total occlusion of a coronary artery”.
The resuscitation time with continued intervention has been on average 30 minutes, but with a large variation of up to 90 minutes of CPR. The longest LUCAS treatment time of a survivor was 50 minutes.
“This is the first full length article on a larger group of patients with cardiac arrests that occur during an intervention, and which are immediately treated with LUCAS CPR and continued PCI (percutaneous coronary intervention). It shows the value of having a LUCAS device stand by in every cath lab or hospital”, says Erik von Schenck, CEO of Jolife AB, which develops and manufactures the device. “In addition to this latest study, there are several more abstracts and presentations confirming the same life-saving benefits and usefulness of LUCAS in this setting, presented at congresses in Europe and US the latest years.”
The study which is made on the pneumatic LUCAS 1 (model V1 and V2) is available electronically “in press” at the website of the journal of Resuscitation: www.resuscitationjournal.com: Wagner et al: “Cardiac arrest in the catheterisation laboratory: A 5-year experience of using mechanical chest compressions to facilitate PCI during prolonged resuscitation efforts”.
About LUCAS CPR
LUCAS Chest Compression System is an easy-to-use and lightweight device that provides quality chest compressions according to the European Resuscitation Council and American Heart Association Guidelines for CPR (cardiopulmonary resuscitation). It assists rescuers in maintaining vital blood circulation in cardiac arrest patients. LUCAS is simple to use, applied within seconds and feasible for use in a majority of cardiac arrest patients. LUCAS is available in an electrically driven version (LUCAS 2) and a pneumatically driven (LUCAS 1). The mechanical CPR device has shown to increase operational efficacy and to improve the opportunities to save cardiac arrest patients.
About Jolife AB
Jolife AB, founded in 2000, develops and manufactures the LUCAS Chest Compression System. Jolife works closely with leading physicians and paramedics and is committed to research and development in order to continue to offer innovative products. The LUCAS Chest Compression Systems are sold in the major markets in the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc., a division of Medtronic Inc. – except in Sweden, Norway and Finland, where Jolife sells directly.